We are live on ! Find out more
MB

MPM BioImpact Portfolio holdings

AUM $1.64B
1-Year Est. Return 245.64%
This Fund
S&P 500
This Quarter Est. Return
-5.58%
1 Year Est. Return
+245.64%
3 Year Est. Return
+550.3%
5 Year Est. Return
+647.56%
10 Year Est. Return
–
AUM
$360M
AUM Growth
-$12.6M
Cap. Flow
+$26.7M
Cap. Flow %
7.41%
Top 10 Hldgs %
69.65%
Holding
41
New
4
Increased
3
Reduced
1
Closed
4

Top Buys

Rank Stock Value
1
IOVA icon
Iovance Biotherapeutics
IOVA
+$15.7M
2
INBX
Inhibrx, Inc. Common Stock
INBX
+$15.1M
3
NTLA icon
Intellia Therapeutics
NTLA
+$7.11M
4
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$3.31M
5
GERN icon
Geron
GERN
+$3.23M

Top Sells

Rank Stock Value
1
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$9.43M
2
AXSM icon
Axsome Therapeutics
AXSM
+$4.13M
3
RLMD icon
Relmada Therapeutics
RLMD
+$3.73M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$3.67M
5
CYTK icon
Cytokinetics
CYTK
+$1.21M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CGEM icon
1
Cullinan Oncology
CGEM
$1.4B
$98.1M 27.24%
7,648,268
– –
ITOS
2
DELISTED
iTeos Therapeutics
ITOS
$36M 9.99%
1,745,943
– –
RPTX
3
DELISTED
Repare Therapeutics
RPTX
$22.9M 6.37%
1,639,849
– –
MRUS
4
DELISTED
Merus
MRUS
$20.8M 5.78%
919,482
– –
NTLA icon
5
Intellia Therapeutics
NTLA
$1.8B
$15.5M 4.3%
299,409
+140,000
+88% +$7.11M
IOVA icon
6
Iovance Biotherapeutics
IOVA
$3.63B
$13.2M 3.68%
+1,200,000
New +$15.7M
GERN icon
7
Geron
GERN
$970M
$13.1M 3.63%
8,434,991
+2,285,714
+37% +$3.23M
INBX
8
DELISTED
Inhibrx, Inc. Common Stock
INBX
$11.6M 3.23%
+1,023,325
New +$15.1M
TCRR
9
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$9.78M 2.72%
3,370,982
– –
HOWL icon
10
Werewolf Therapeutics
HOWL
$45.8M
$9.77M 2.71%
2,388,011
– –
CYTK icon
11
Cytokinetics
CYTK
$10B
$7.63M 2.12%
194,246
-30,000
-13% -$1.21M
CRNX icon
12
Crinetics Pharmaceuticals
CRNX
$9B
$6.84M 1.9%
366,676
– –
BCRX icon
13
BioCryst Pharmaceuticals
BCRX
$2.51B
$6.76M 1.88%
639,089
– –
TVTX icon
14
Travere Therapeutics
TVTX
$6.19B
$6.74M 1.87%
277,950
– –
YMAB
15
DELISTED
Y-mAbs Therapeutics
YMAB
$6.71M 1.86%
443,702
– –
HRMY icon
16
Harmony Biosciences
HRMY
$2.28B
$6.71M 1.86%
137,517
– –
HARP
17
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$6.11M 1.7%
319,671
– –
MIRM icon
18
Mirum Pharmaceuticals
MIRM
$5.94B
$5.62M 1.56%
288,531
– –
ARQT icon
19
Arcutis Biotherapeutics
ARQT
$2.99B
$5.51M 1.53%
258,500
– –
RETA
20
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$5.47M 1.52%
180,000
– –
FOLD
21
DELISTED
Amicus Therapeutics
FOLD
$5.32M 1.48%
495,603
– –
EPZM
22
DELISTED
Epizyme, Inc
EPZM
$5.04M 1.4%
3,425,202
– –
GTHX
23
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$4.23M 1.18%
856,798
– –
VSTM icon
24
Verastem
VSTM
$654M
$3.76M 1.05%
270,388
– –
MDGL icon
25
Madrigal Pharmaceuticals
MDGL
$12.3B
$3.22M 0.89%
+45,000
New +$3.31M
1
2

Similar funds

OCM
Opti Capital Management New York $1.64B AUM 0% 1-Year Est. Return
LFS
Lutz Financial Services Omaha, Nebraska $1.64B AUM 15.04% 1-Year Est. Return
TIM
Triodos Investment Management Driebergen-Rijsenburg, Netherlands $1.64B AUM 37.98% 1-Year Est. Return
AAG
Armstrong Advisory Group Needham, Massachusetts $1.64B AUM 19.37% 1-Year Est. Return
MRG
Milestone Resources Group Road Town Tortola, British Virgin Islands $1.64B AUM 2.87% 1-Year Est. Return
EPW
Evolve Private Wealth Los Angeles, California $1.64B AUM
TWM
Tradition Wealth Management Edina, Minnesota $1.64B AUM 26.59% 1-Year Est. Return
MA
MONECO Advisors Fairfield, Connecticut $1.64B AUM 25.43% 1-Year Est. Return

MPM BioImpact's Q2 2022 Portfolio in Review

As of Q2 2022, MPM BioImpact held 41 positions worth $360M, down 3.4% from $373M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

MPM BioImpact deployed $26.7M of net new capital in Q2 2022, opening 4 new positions and adding to 3 existing holdings. Its largest new stake was Iovance Biotherapeutics: 1,200,000 shares worth $13.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Cytokinetics, an estimated $1.21M trimmed.

  • MPM BioImpact's largest Q2 2022 buy was Iovance Biotherapeutics: 1,200,000 shares worth $13.2M.
  • MPM BioImpact added most to Intellia Therapeutics in Q2 2022, an estimated $7.11M increase.
  • MPM BioImpact's biggest Q2 2022 reduction was Cytokinetics, cutting an estimated $1.21M.
  • MPM BioImpact fully exited Turning Point Therapeutics, Inc. Common Stock in Q2 2022, selling an estimated $9.43M.
  • MPM BioImpact's ten largest holdings make up 70% of its $360M portfolio in Q2 2022.
  • MPM BioImpact opened 4 new positions and closed 4 in Q2 2022.
  • MPM BioImpact's portfolio value fell 3.4% quarter-over-quarter to $360M.

Based on MPM BioImpact's 13F filing for Q2 2022, filed 11 Aug 2022.